Combined hepatocellular-cholangiocarcinoma

Clinical trials for Combined hepatocellular-cholangiocarcinoma explained in plain language.

Never miss a new study

Get alerted when new Combined hepatocellular-cholangiocarcinoma trials appear

Sign up with your email to follow new studies for Combined hepatocellular-cholangiocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1 Not yet finished but already full! 1

New drug cocktail aims to stop rare liver cancer from coming back

Disease control Not yet recruiting

This study tests whether combining an immunotherapy drug (cadonilimab) with a chemotherapy pill (capecitabine) can prevent a rare mixed liver cancer from returning after surgery. About 75 adults who had their tumor completely removed but are at medium-to-high risk of recurrence w…

Matched conditions: COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA

Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control

Last updated Jun 27, 2026 07:59 UTC

Combined hepatocellular-cholangiocarcinoma

Get alerted when new Combined hepatocellular-cholangiocarcinoma trials appear

New drug cocktail aims to stop rare liver cancer from coming back